Life sciences executive compensation is among the most opaque segments of the US senior hiring market. Published benchmarks are sparse, survey data is unreliable at the C-suite level, and the structural differences between a pre-clinical biotech, a Phase 3 company preparing for commercial launch, and an established pharmaceutical company make aggregate numbers nearly meaningless. This report attempts to cut through that opacity using the only data source we trust: 395 signed-and-accepted formal offers from life sciences placements we completed between January 2025 and Q1 2026.
Every number in this report comes from a real offer for a real executive who accepted the role and is now doing the job. We do not use survey data, compensation committee projections, or self-reported figures. The dataset covers roles from Chief Medical Officer through VP-level functional leadership across biotech, pharmaceutical, medical device, and life sciences services companies headquartered or operating principally in the United States.
The headline: stage determines everything
If you take one insight from this report, take this: company stage is the single most powerful predictor of life sciences executive compensation, more powerful than title, therapeutic area, geography, or individual negotiating skill. A Chief Medical Officer at a pre-clinical biotech and a CMO at a commercial-stage pharmaceutical company hold the same title and often have comparable credentials. Their total compensation packages differ by a factor of two or more, and the structure of those packages — the ratio of base salary to equity, the type of equity, the vesting triggers — is fundamentally different.
This stage-dependency is more pronounced in life sciences than in any other sector we cover. In technology, a VP Engineering at a Series C company and a VPE at a public company differ in comp by perhaps 40% to 60%. In life sciences, the equivalent spread is 80% to 120%. The reason is structural: life sciences companies at earlier stages are compensating for dramatically higher binary risk (the drug either works or it doesn’t, and if it doesn’t, the company may cease to exist) with commensurately larger equity grants at lower base salaries.
CMO and CSO compensation
Chief Medical Officer compensation in our 2025–2026 dataset ranges from $450K to $750K in total compensation at grant, with the median sitting at $585K. The spread is driven almost entirely by company stage:
At pre-clinical companies (typically Series A/B, 10–30 employees), CMO base salaries run $280K to $340K with target bonuses of 25% to 35% of base. Equity grants are the largest component: 0.5% to 1.2% of fully diluted shares, valued at the most recent 409A, which at early-stage valuations often represents $400K to $900K on paper. Total compensation at grant for a pre-clinical CMO sits at $450K to $550K, with the understanding that the equity component carries substantial binary risk.
At Phase I–III companies (typically Series C/D, 50–200 employees), CMO base salaries rise to $380K to $460K with target bonuses of 35% to 50%. Equity grants are smaller on a percentage basis (0.2% to 0.6%) but larger in dollar terms due to higher company valuations, typically $500K to $1.2M at grant. Total compensation at grant for a clinical-stage CMO ranges $580K to $720K.
At commercial-stage companies (post-NDA approval, revenue-generating), CMO total compensation reaches $650K to $750K or higher, with base salaries of $440K to $520K, bonuses of 40% to 60%, and annual equity refreshes that are structured more like public-company executive grants than venture-stage option packages.
Chief Scientific Officer compensation tracks roughly 15% to 20% below CMO levels across all stages. Our 2025–2026 data shows CSO total compensation ranging from $380K to $620K, with the median at $485K. The discount relative to CMOs reflects the market’s pricing of clinical development experience (which the CMO brings) versus discovery and translational science expertise (which the CSO brings) — clinical development is closer to the revenue-generating event (regulatory approval and commercialization) and is compensated accordingly.
VP Clinical Operations and Regulatory
Below the C-suite, two VP-level functions stand out in our dataset for both compensation levels and hiring velocity: Clinical Operations and Regulatory Affairs.
VP Clinical Operations is the most actively recruited VP-level role in our life sciences practice. We placed 23 VP Clinical Ops executives in 2025, more than any other single life sciences title. Median total compensation was $310K, with a range from $250K to $380K. The lower end of the range corresponds to companies running small, focused Phase 1/2 programs; the upper end corresponds to companies managing complex, multi-site, multi-country Phase 3 registrational trials. The correlation between trial complexity and VP Clinical Ops compensation is tighter than any other role-to-comp relationship in our dataset.
VP Regulatory Affairs compensation is slightly lower than VP Clinical Ops at the median ($285K versus $310K) but shows less variance. The range in our dataset runs from $220K to $340K. Regulatory professionals command a premium when they bring specific therapeutic-area depth — a VP Regulatory who has shepherded multiple oncology INDs through FDA is compensated differently from a generalist regulatory leader, and the premium for oncology and immunology regulatory expertise in our 2025 data was approximately 12% above the overall VP Regulatory median.
Sign-on bonuses for both VP Clinical Ops and VP Regulatory have grown materially. Median sign-on in our 2025 dataset was $45K for VP Clinical Ops and $35K for VP Regulatory, up from $25K and $20K respectively in our 2023 data. The increase reflects the tight market for experienced clinical and regulatory leaders, particularly those with direct NDA/BLA filing experience.
Commercial leadership compensation
Commercial leadership in life sciences — VP Commercial, VP Market Access, Head of Medical Affairs, and Chief Commercial Officer roles — commands compensation that is among the highest in the life sciences VP tier, driven by the direct connection between commercial execution and revenue generation.
In our 2025–2026 dataset, VP Commercial / Head of Commercial at companies in the pre-launch or early-launch phase showed median total compensation of $345K, with a range from $280K to $420K. The variance is driven primarily by the size and complexity of the launch — a company launching a single product in a specialty market pays differently from a company launching across multiple indications with a field force of 200+ representatives.
Chief Commercial Officer roles at companies with established commercial operations showed median total compensation of $520K to $680K, with equity grants that are heavily weighted toward revenue milestones. In several of our 2025 placements, the CCO’s equity vesting was explicitly tied to achieving specific revenue thresholds in the first 18 months post-launch — a structure that aligns the executive’s incentives with commercial success but introduces meaningful compensation risk if the launch underperforms.
Compensation by company stage
The stage-based framework is the most useful lens for understanding life sciences executive compensation. Our dataset breaks cleanly into four stage categories, each with distinct compensation structures:
Pre-clinical (Series A/B): Lower base salaries ($250K–$380K for C-suite, $180K–$260K for VP level), larger equity grants as a percentage of the company, minimal or no sign-on bonuses, and limited severance protections. The implicit deal: you take a below-market cash package in exchange for a meaningful equity stake in a company whose value will be determined by a single clinical data readout that may be two to four years away.
Phase I–II (Series B/C): Base salaries approach market for the title ($320K–$450K for C-suite, $220K–$310K for VP level), equity grants are mid-range (0.15%–0.5% for C-suite), and sign-on bonuses begin to appear as a competitive tool. Clinical milestone bonuses — cash or equity payments triggered by specific development milestones like IND clearance, first patient dosed, or Phase 2 data readout — are common and often represent 15% to 25% of target annual compensation.
Phase III / Pre-commercial (Series D/E or post-IPO): Compensation approaches or meets market parity with established pharma. Base salaries of $380K–$520K for C-suite, VP compensation at $260K–$380K, with equity that is now more liquid (for post-IPO companies) or closer to a liquidity event (for late-stage private companies preparing to go public). This is the stage where life sciences executive compensation most closely resembles technology executive compensation in structure.
Commercial stage: Full market-rate cash compensation, annual equity refreshes, and bonus structures tied to revenue and profitability rather than development milestones. At this stage, life sciences executive compensation converges with general industry executive compensation benchmarks, though therapeutic-area specialization continues to create premiums for executives with specific franchise experience.
Equity structures in life sciences
Equity in life sciences requires different analytical tools than equity in technology, primarily because the value-creation events in life sciences are more binary and more concentrated in time. A technology company builds value gradually through revenue growth; a biotech company’s value can double or halve on a single data readout.
The practical implications for executive compensation negotiation are significant. Vesting acceleration on change of control is more important in life sciences than in technology, because M&A is the most common liquidity path for clinical-stage biotechs — and acquisitions often happen at the point of maximum clinical data value, before the executive’s equity has fully vested under a standard 4-year schedule. In our 2025 dataset, 72% of C-suite offers at clinical-stage companies included some form of change-of-control acceleration, compared to 48% in our technology C-suite dataset.
Milestone-based vesting is a distinctive feature of life sciences equity that has no direct parallel in technology. In our 2025 dataset, 34% of VP-level and above offers included equity tranches that vest upon achievement of specific clinical or regulatory milestones rather than on a time schedule. These milestone grants are in addition to standard time-vesting equity and represent incremental compensation for executives who successfully navigate the development process.
For professionals evaluating life sciences executive offers, the right framework is to analyze equity not as a single number but as a portfolio of time-vesting and milestone-vesting components, each with different risk profiles and different expected values depending on the company’s clinical trajectory. A $500K equity grant that is 100% time-vesting has a very different expected value from a $500K grant that is 50% time-vesting and 50% milestone-vesting tied to Phase 3 data readout.
Methodology & caveats
This report is built from 395 verified, signed-and-accepted formal offers from life sciences placements made by Alden Search between January 2025 and Q1 2026. All compensation figures are gross (pre-tax), in nominal US dollars. Equity is valued at grant using the company’s most recent 409A valuation for private companies and the trailing 30-day average closing price for public companies. Target bonuses are reported at target, not actual payout. Clinical milestone bonuses are reported at target achievement levels.
The dataset covers companies headquartered or operating principally in the United States, with concentrations in the Boston/Cambridge, San Francisco Bay Area, San Diego, Research Triangle, Philadelphia, and emerging Miami markets. Geographic compensation adjustments are noted where relevant in the text.
This report does not constitute compensation advice. Individual outcomes vary based on candidate qualifications, company budget, therapeutic area, development stage, and market conditions at the time of negotiation. For questions about the data or to discuss how your current compensation compares to our dataset, contact malcolm.sheffield@aldensearch.com.
This piece is authored by Victoria Ashford (Managing Partner) with substantial contributions from Malcolm Sheffield on the life sciences practice and the Alden Search research team on data assembly and analysis.